“…However, up to 50% of LLS CRC exhibits biallelic somatic inactivation of DNA MMR genes within the tumor (Geurts-Giele et al, 2014;Haraldsdottir et al, 2014;Kang et al, 2015;Rodriguez-Soler et al, 2013;Sourrouille et al, 2013). It has now been demonstrated that many of these are due to constitutional mutations and epimutations in other genes, including POLD1 and POLE (Haraldsdottir et al, 2014;Palles et al, 2013), MUTYH (Castillejo et al, 2014;Syngal et al, 2015), FAN1 (Segui et al, 2015), NTHL1 (Weren et al, 2015), PIK3CA (Cohen et al, 2016), BRCA1/2, 2 PTEN, STK11 (Yurgelun et al, 2015) and other cancer susceptibility genes (SMAD4, BMPR1A, KLLN, AKT1, AXIN2, BUB1 and BUB3) (Hansen et al, 2017) with some resultant tumours sometimes acquiring two somatic mutations in the same MMR gene, and consequently dMMR and/or MSI (Frayling and Arends, 2015;Short et al, 2015). Biallelic MSH3 mutations have also been identified as predisposing to MSI CRC, however this occurs in longer repeats than is currently investigated by conventional MSI testing.…”